BridgePort Financial Solutions LLC Has $864,000 Position in Bristol Myers Squibb Company $BMY

BridgePort Financial Solutions LLC boosted its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 228.4% during the fourth quarter, HoldingsChannel.com reports. The fund owned 16,021 shares of the biopharmaceutical company’s stock after purchasing an additional 11,143 shares during the period. BridgePort Financial Solutions LLC’s holdings in Bristol Myers Squibb were worth $864,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in BMY. Brighton Jones LLC lifted its holdings in shares of Bristol Myers Squibb by 33.4% during the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock valued at $1,116,000 after acquiring an additional 4,935 shares during the period. Sivia Capital Partners LLC grew its holdings in shares of Bristol Myers Squibb by 59.4% in the 2nd quarter. Sivia Capital Partners LLC now owns 7,477 shares of the biopharmaceutical company’s stock worth $346,000 after purchasing an additional 2,786 shares during the last quarter. United Bank increased its position in shares of Bristol Myers Squibb by 15.0% during the 2nd quarter. United Bank now owns 25,148 shares of the biopharmaceutical company’s stock worth $1,164,000 after purchasing an additional 3,277 shares in the last quarter. VestGen Advisors LLC lifted its holdings in Bristol Myers Squibb by 18.7% during the 2nd quarter. VestGen Advisors LLC now owns 4,474 shares of the biopharmaceutical company’s stock valued at $207,000 after purchasing an additional 706 shares during the last quarter. Finally, Fisher Asset Management LLC lifted its holdings in Bristol Myers Squibb by 2.8% during the 2nd quarter. Fisher Asset Management LLC now owns 226,976 shares of the biopharmaceutical company’s stock valued at $10,507,000 after purchasing an additional 6,237 shares during the last quarter. Institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Price Performance

Shares of BMY stock opened at $59.57 on Friday. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $62.89. The company has a current ratio of 1.26, a quick ratio of 1.14 and a debt-to-equity ratio of 2.32. The firm’s 50 day moving average is $59.27 and its 200-day moving average is $52.57. The firm has a market capitalization of $121.63 billion, a price-to-earnings ratio of 17.27, a PEG ratio of 0.18 and a beta of 0.27.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The company had revenue of $12.50 billion during the quarter, compared to analyst estimates of $12.24 billion. During the same period in the prior year, the business earned $1.67 EPS. The business’s revenue for the quarter was up 1.3% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Sell-side analysts forecast that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd will be given a dividend of $0.63 per share. The ex-dividend date is Thursday, April 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.2%. Bristol Myers Squibb’s payout ratio is presently 73.04%.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on BMY. Guggenheim reaffirmed a “buy” rating and set a $72.00 price objective (up from $62.00) on shares of Bristol Myers Squibb in a research note on Friday, February 6th. Scotiabank reissued a “sector perform” rating and issued a $60.00 target price (up from $53.00) on shares of Bristol Myers Squibb in a report on Friday, January 9th. Leerink Partners increased their price target on Bristol Myers Squibb from $54.00 to $60.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 13th. Citigroup lifted their price objective on Bristol Myers Squibb from $60.00 to $64.00 and gave the company a “neutral” rating in a research report on Friday, February 6th. Finally, Bank of America raised Bristol Myers Squibb from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $52.00 to $61.00 in a research note on Monday, December 15th. Nine investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $61.41.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Positive Phase 3 data for Camzyos (SCOUT‑HCM) in adolescents may expand the label/profile for BMY’s cardiac myosin inhibitor, strengthening the late‑stage pipeline and future revenue potential. SCOUT‑HCM Trial Results
• Positive Sentiment: Janux Therapeutics triggered a $35M milestone under its collaboration with BMY after nominating a development candidate — a near‑term cash/partner validation and a de‑risking signal for partnered R&D. Janux Milestone
• Positive Sentiment: Unusually large call‑option activity (≈66,900 calls traded) indicates speculative bullish interest from traders positioning for upside. (Market data entry)
• Positive Sentiment: Analyst commentary and screens (Zacks/Trefis pieces) highlight BMY’s history of earnings surprises and a view that the company has ingredients to beat upcoming results — supportive for investor sentiment. Analyst Coverage
• Neutral Sentiment: Analyses project HNSCC market growth to ~$4.5B by 2034 (CAGR ≈8.4%), a long‑term addressable market note that may matter if BMY advances therapies in that space. HNSCC Market Outlook
• Neutral Sentiment: Reports on growth in the advanced renal cell carcinoma market highlight broader oncology tailwinds that include BMY among peers — useful context but not an immediate stock catalyst. RCC Market Report
• Neutral Sentiment: BMY published community and program updates around multiple myeloma care and equity initiatives — positive for ESG/community positioning but unlikely to move near‑term revenue. Community Program Release
• Negative Sentiment: Insider selling: EVP David V. Elkins sold 30,000 shares at ~$61.67 on April 1 (Form 4 filing), reducing his stake ~15.9% — an action investors may view negatively even if it’s routine. Insider Form 4
• Negative Sentiment: Recent quarterly results (reported Feb. 5) showed an EPS miss ($1.26 vs. $1.65 est.), even as revenue slightly beat; that earnings disappointment and investor focus on near‑term profitability remain headwinds despite FY‑26 guidance of $6.05–$6.35. (Company filings/earnings release)

Insider Activity

In other news, EVP David V. Elkins sold 30,000 shares of the company’s stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the transaction, the executive vice president owned 159,248 shares of the company’s stock, valued at $9,820,824.16. This represents a 15.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.09% of the stock is owned by company insiders.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.